Advertisement

Vecuronium (ORG-NC-45)

  • W. C. Bowman
  • G. A. Sutherland
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 79)

Abstract

Vecuronium bromide (ORG-NC-45, Norcuron), henceforth called simply vecuronium, is the monoquaternary homologue of pancuronium. Vecuronium differs from pancuronium in that the methyl group on the 203b2-nitrogen atom of the latter is lacking (Fig. 1). Vecuronium is one of a series of amino steroidal derivatives, the synthesis and chemical properties of which have been described by Buckett et al. (1973), and more recently by Savage (1980, 1981) and Savage et al. (1980). Vecuronium was selected for further study from a series of closely related analogues on the grounds that, in the cat, it exhibited pronounced neuromuscular blocking activity coupled with only very weak actions at sympathetic ganglia and on the cardiac vagus (Durant et al. 1979 c). Since the first description of its properties, vecuronium has undergone extensive additional study both in animals (as described in this chapter) and in humans (as described by Miller in Chap. 28). Much of the work up to the end of 1979 is described in the proceedings of a symposium edited by Bowman and Norman (1980), and short reviews have also been published by Booij et al. (1981 a) and Durant (1982). With the knowledge of structure-activity relations available at the time, Durant et al. (1979 c) concluded that the conformation of the D ring acetylcholine-like fragment of pancuronium, which is known to have a different molecular geometry and electronic structure from that of the A ring (Savage et al. 1971), while intrinsically suited to the neuromuscular cholinoceptor, is relatively incompatible with the cardiac muscarinic receptor.

Keywords

Muscarinic Receptor Vagal Stimulation Neuromuscular Blocking Tibialis Anterior Muscle Transpulmonary Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbs ET, Joseph DN (1981) The effects of atropine and oxotremorine on acetylcholine release in rat phrenic nerve-diaphragm preparations. Br J Pharmacol 73:481–482PubMedGoogle Scholar
  2. Baird WLM, Bowman WC, Kerr WJ (1982) Some actions of Org NC 45 and of edrophonium in the anaesthetized cat and in man. Br J Anaesth 54:375–385PubMedCrossRefGoogle Scholar
  3. Blogg CE, Savege TM, Simpson JC, Ross LA, Simpson BR (1973) A new muscle relaxant — AH8165. Proc R Soc Med 66:1023–1027PubMedGoogle Scholar
  4. Booij LHDJ, Edwards RP, Sohn YJ, Miller RD (1980) Cardiovascular and neuromuscular effects of Org NC 45, pancuronium, metocurine and d-tubocurarine in dogs. Anesth Analg (Cleve) 59:26–30Google Scholar
  5. Booij LHDJ, Vree TB, Crul JF (1981 a) Org NC45: A new nondepolarizing muscle-relaxant with a steroid structure (in Dutch). TGO Tijdschr Geneesmidelenonderzoek 6:1055–1059Google Scholar
  6. Booij LHDJ, Vree TB, Hurkmans F, Reekers-Ketting JJ, Crul JF (1981 b) Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC 45 and each of its hydroxy metabolites in dogs. Anaesthesist 30:329–333PubMedGoogle Scholar
  7. Bowman WC (1964) Neuromuscular blocking agents. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities. Academic, London, pp 325–351 (Pharmacometrics, vol 1, chap 16)Google Scholar
  8. Bowman WC (1980 a) Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg (Cleve) 59:935–943Google Scholar
  9. Bowman WC (1980 b) A new nondepolarizing neuromuscular blocking drug. Trends Pharmacol Sci 1:263–266CrossRefGoogle Scholar
  10. Bowman WC (1980 c) Pharmacology of neuromuscular function. John Wright, BristolGoogle Scholar
  11. Bowman WC (1981) New neuromuscular blocking drugs and their antagonists. Indian J Pharmacol 13:1–22Google Scholar
  12. Bowman WC (1982) Non-relaxant properties of neuromuscular blocking drugs. Br J An-aesth 54:147–160Google Scholar
  13. Bowman WC, Marshall IG (1981) Die Rolle prä- und postsynaptischer cholinergischer Rezeptoren bei der neuromuskulären Übertragung und deren Beeinflußbarkeit durch Muskelrelaxantien. In: Buzello W (ed) Muskelrelaxantien. Georg Thieme, Stuttgart, pp 34–48Google Scholar
  14. Bowman WC, Norman J (eds) (1980) Symposium on Org NC 45. Br J Anaesth 52 [Suppl 1]:1–72SGoogle Scholar
  15. Bowman WC, Webb SN (1972) Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat. J Pharm Pharmacol 24:762–772PubMedCrossRefGoogle Scholar
  16. Brown BR, Crout JR (1970) The sympathomimetic effect of gallamine on the heart. J Pharmacol Exp Ther 172:266–273PubMedGoogle Scholar
  17. Buckett WR, Hewett CL, Savage DS (1973) Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. J Med Chem 16:1116–1124PubMedCrossRefGoogle Scholar
  18. Clark AL, Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323–331PubMedGoogle Scholar
  19. Colquhoun D, Sheridan RE (1981) Modes of action of gallam ine. Proc R Soc Lond [Biol] 211:181–203CrossRefGoogle Scholar
  20. Colquhoun D, Dreyer F, Sheridan RE (1979) The actions of tubocurarine at the frog neuromuscular junction. J Physiol (Lond) 293:247–284Google Scholar
  21. Cox B, Ennis C (1982) Tryptamine-induced inhibition of serotonin release from rat hypothalamic slices is mediated via a cholinergic interneurone. Br J Pharmacol 76:242PGoogle Scholar
  22. Cronnelly R, Gencarelli P, Miller RD, Fisher DM, Nguyen L (1982) Pharmacokinetics of pancuronium and Org NC 45 (Norcuron). Anesth Analg (Cleve) 61:176–177Google Scholar
  23. De La Lande IS, Rand MJ (1965) A simple isolated nerve-blood vessel preparation. Aust J Exp Biol Med Sci 43:639–656PubMedCrossRefGoogle Scholar
  24. Docherty J, McGrath JC (1978) Sympathomimetic effects of pancuronium bromide on the cardiovascular system of the pithed rat: a comparison with the effects of drugs blocking the neuronal uptake of noradrenaline. Br J Pharmacol 64:589–599PubMedGoogle Scholar
  25. Docherty JR, McGrath JC (1980) A comparison of the effects of pancuronium bromide and its monoquaternary analogue Org NC 45 on autonomic and somatic neurotransmission in the rat. Br J Pharmacol 71:225–233PubMedGoogle Scholar
  26. Domenach JS, Garcia RC, Sasiain JMR, Loyala A, Oroz JS (1976) Pancuronium bromide: an indirect sympathomimetic agent. Br J Anaesth 48:1143–1148CrossRefGoogle Scholar
  27. Dreyer F (1981) Molekulare Grundlagen der neuromuskulären Blockade. In: Buzello W (ed) Muskelrelaxantien. Georg Thieme, Stuttgart, pp 15–34Google Scholar
  28. Durant NN (1978) Studies on neuromuscular blocking and facilitatory agents. PhD Thesis, University of StrathclydeGoogle Scholar
  29. Durant NN (1982) Norcuron®, a new nondepolarizing neuromuscular blocking agent. Semin Anesth 1:47–56Google Scholar
  30. Durant NN, Houwertjes MC, Agoston S (1979 a) Renal elimination of Org NC 45 and pancuronium. Anesthesiology 51:S266CrossRefGoogle Scholar
  31. Durant NN, Houwertjes MC, Agoston S (1979 b) Hepatic elimination of Org NC 45 and pancuronium. Anesthesiology 51:S267CrossRefGoogle Scholar
  32. Durant NN, Marshall IG, Savage DS, Nelson DJ, Sleigh T, Carlyle IC (1979 c) The neuromuscular and autonomic blocking activities of pancuronium analogues in the cat. J Pharm Pharmacol 31:831–836PubMedCrossRefGoogle Scholar
  33. Durant NN, Houwertjes MC, Crul JF (1980) Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat, and rhesus monkey. Br J An-aesth 52:723–730Google Scholar
  34. Durant NN, Nguyen N, Lee C, Katz RL (1981) The cumulative effects of norcuron and atracurium. Anesthesiology 55:A209Google Scholar
  35. Edwards RP, Miller RD, Roizen MF, Ham J, Way WL, Lake CR, Roderick L (1979) Cardiac responses to imipramine and pancuronium during anesthesia with halothane or enflurane. Anesthesiology 50:421–425PubMedCrossRefGoogle Scholar
  36. Fahey MR, Morris RB, Miller RD, Sohn YJ, Cronnelly R, Gencareli P (1981) Clinical pharmacology of Org NC 45 (Norcuron™). Anesthesiology 55:6–11PubMedCrossRefGoogle Scholar
  37. Foldes FF (1978) Enzymes of acetylcholine metabolism. In: Foldes FF (ed) Enzymes in anesthesiology. Springer, Berlin Heidelberg New York, pp 91–168CrossRefGoogle Scholar
  38. Foldes FF, Chaudry I, Ohta Y, Amaki Y, Nagashima H, Duncalf D (1981) The influence of stimulation parameters on the potency and reversibility of neuromuscular blocking agents. J Neural Transm 52:227–249PubMedCrossRefGoogle Scholar
  39. Fosbraey P, Johnson ES (1980) Release-modulating acetylcholine receptors on cholinergic neurones of the guinea-pig ileum. Br J Pharmacol 68:289–300PubMedGoogle Scholar
  40. Frahley DS, Lemoncelli GL, Coleman A (1978) Severe hypertension associated with pancuronium bromide. Anesth Analg (Cleve) 57:265–267Google Scholar
  41. Funk DI, Crul JF, Van Der Pol FM (1980) Effects of changes in acid-base balance on neuromuscular blockade produced by Org NC 45. Acta Anaesth Scand 24:119–124PubMedCrossRefGoogle Scholar
  42. Furchgott RF (1981) The requirement of endothelial cells in the relaxation of arteries by acetylcholine and some other vasodilators. Trends Pharmacol Sci 2:173CrossRefGoogle Scholar
  43. Galindo A (1971) Prejunctional effect of curare: its relative importance. J Neurophysiol 34:289PubMedGoogle Scholar
  44. Galindo A (1972) Curare and pancuronium compared: effects on previously undepressed myoneural junction. Science 178:753PubMedCrossRefGoogle Scholar
  45. Gandiha A, Marshall IG, Paul D, Rodger IW, Scott W, Singh H (1975) Some actions of chadonium iodide, a new short-acting muscle relaxant in anaesthetised cats and isolated preparations. Clin Exp Pharmacol Physiol 2:159–170PubMedCrossRefGoogle Scholar
  46. Gardier RW, Tsevdos EJ, Jackson DB, Delaunois AL (1978) Distinct muscarinic mediation of suspected dopaminergic activity in sympathetic ganglia. Fed Proc 37:2422–2428PubMedGoogle Scholar
  47. Greengard P, Kebabian JW (1974) Role of cyclic AMP in synaptic transmission in the mammalian peripheral nervous system. Fed Proc 33:1059–1067PubMedGoogle Scholar
  48. Guyton AC, Reeder RC (1950) Quantitative studies on the autonomic effects of curare. J Pharmacol Exp Ther 98:188–193PubMedGoogle Scholar
  49. Hoppe JO (1951) A new series of synthetic curare-like compounds. Ann NY Acad Sci 54:395–406PubMedCrossRefGoogle Scholar
  50. Hubbard JI, Wilson DF (1973) Neuromuscular transmission in a mammalian preparation in the absence of blocking drugs, and the effect of d-tubocurarine. J Physiol (Lond) 228:307–326Google Scholar
  51. Hughes R, Chappie DJ (1981) The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 53:31–44PubMedCrossRefGoogle Scholar
  52. Hughes R, Payne JP, Sugai N (1976) Studies on fazodinium bromide (AH 8165): a new nondepolarizing neuromuscular blocking agent. Can Anaesth Soc J 23:36–47PubMedCrossRefGoogle Scholar
  53. Ivankovich AD, Miletich DJ, Albrecht RF, Zahed B (1975) The effect of pancuronium on myocardial contraction and catecholamine metabolism. J Pharm Pharmacol 27:837–841PubMedCrossRefGoogle Scholar
  54. Katz B, Miledi R (1978) A re-examination of curare action at the motor end-plate. Proc R Soc Lond [Biol] 203:119–133CrossRefGoogle Scholar
  55. Kelman GR, Kennedy BR (1971) Cardiovascular effects of pancuronium in man. Br J An-aesth 43:335–338Google Scholar
  56. Krieg N, Crul JF, Booij LHDJ (1980 a) Relative potency of Org NC 45, pancuronium, me-tocurine and tubocurarine in anaesthetized man. Br J Anaesth 52:783–788PubMedCrossRefGoogle Scholar
  57. Krieg N, Rutten JMJ, Crul JF, Booij LHDJ (1980 b) Preliminary review of the interactions of Org NC 45 with anaesthetics and antibiotics in animals. Br J Anaesth 52 [Suppl 1]:33–36SGoogle Scholar
  58. Lee C, Yang E, Lippmann M (1980) Constrictive effect of pancuronium on capacitance vessels. Br J Anaesth 52:261–263PubMedCrossRefGoogle Scholar
  59. Lee Son L, Waud BE, Waud DR (1981) A Comparison of the neuromuscular blocking and vagolytic effects or Org NC 45 and pancuronium. Anesthesiology 55:12–18CrossRefGoogle Scholar
  60. Lee Son S, Waud BE (1977) Potencies of neuromuscular blocking agents at the receptors of the atrial pacemaker and motor end plates of the guinea-pig. Anesthesiology 47:34–36CrossRefGoogle Scholar
  61. Lee Son S, Waud DR (1978) A vagolytic action of neuromuscular blocking agents on the cardiac vagus nerve in the guinea-pig atrium. Anesthesiology 48:191–194CrossRefGoogle Scholar
  62. Lee Son S, Waud DR (1980) Effects of nondepolarizing neuromuscular blocking agents on the cardiac vagus nerve in the guinea-pig. Br J Anaesth 52:981–987CrossRefGoogle Scholar
  63. Leung E, Mitchelson F (1982 a) The interaction of pancuronium with cardiac and ileal muscarinic receptors. Eur J Pharmacol 81:1–9CrossRefGoogle Scholar
  64. Leung E, Mitchelson F (1982 b) Modification by hexamethonium of the muscarinic receptor blocking activity of pancuronium and homatropine in isolated tissues of the guinea-pig. Eur J Pharmacol 80:11–17PubMedCrossRefGoogle Scholar
  65. Levy MN, Blatberg B (1976) Effects of vagal stimulation on the overflow of norepinephrine into the coronary sinus during cardiac sympathetic nerve stimulation in the dog. Circ Res 38:81–85PubMedGoogle Scholar
  66. Li CK, Mitchelson F (1978) The effect of stercuronium on cardiac muscarinic receptors. Eur J Pharmacol 51:251–259PubMedCrossRefGoogle Scholar
  67. Löffelholz K, Muscholl E (1970) Inhibition by parasympathetic nerve stimulation of the release of the adrenergic transmitter. Naunyn Schmiedeberg’s Arch Pharmacol 267:181–184CrossRefGoogle Scholar
  68. Marshall IG (1973) The ganglion blocking and vagolytic actions of three short-acting neuromuscular blocking drugs in the cat. J Pharm Pharmacol 25:530–536PubMedCrossRefGoogle Scholar
  69. Marshall IG (1980) Actions of non-depolarizing neuromuscular blocking agents at choli-noceptors other than at the motor endplate. In: Conseiller C et al. (eds) Curares and curarisation. Elsevier/North Holland, New York, pp 257–274Google Scholar
  70. Marshall IG, Agoston S, Booij LDHJ, Durant NN, Foldes FF (1980a) Pharmacology of Org NC 45 compared with other non-depolarizing neuromuscular blocking drugs. Br J Anaesth 52:11–19SCrossRefGoogle Scholar
  71. Marshall IG, Gibb AJ, Durant NN (1983) The neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide and its potential metabolites in the anaesthetized cat. Br J Anaesth 55:703–714PubMedCrossRefGoogle Scholar
  72. Marshall RJ, McGrath JC, Miller RD, Docherty JR, Lamar JC (1980b) Comparison of the cardiovascular actions of Org NC 45 with those produced by other non-depolarizing neuromuscular blocking agents in experimental animals. Br J Anaesth 52:21SGoogle Scholar
  73. Marshall RJ, Ojewole JAO (1979) Comparison of the autonomic effects of some currently used neuromuscular blocking agents. Br J Pharmacol 66:77–78pGoogle Scholar
  74. McDowell SA, Clarke RSJ (1969) A clinical comparison of pancuronium with d-tubocurarine. Anaesthesia 109:190–219Google Scholar
  75. McIndewar IC, Marshall RJ (1981) Interactions between the neuromuscular blocking drug Org NC 45 and some anaesthetic, analgesic and antimicrobial agents. Br J Anaesth 53:785–792PubMedCrossRefGoogle Scholar
  76. Moss J, Rosow CE, Savarese JJ, Philbin DM, Kniffen KJ (1981) Role of histamine in the hypotensive action of tubocurarine in humans, Anesthesiology 55:19–25PubMedCrossRefGoogle Scholar
  77. Nana A, Cardan E, Domokos M (1973) Blood catecholamine chanbges after pancuronium. Acta Anaesth Scand 17:83–87PubMedCrossRefGoogle Scholar
  78. Pauca AL, Skovsted P (1981) Cardiovascular effects of pancuronium in patients anaesthetized with enflurane and fluroxene. Can Anaesth Soc J 28:39–45PubMedCrossRefGoogle Scholar
  79. Quintana A (1977) Effect of pancuronium bromide on the adrenergic reactivity of the isolated rat vas deferens. Eur J Pharmacol 46:275–277PubMedCrossRefGoogle Scholar
  80. Rand MJ, Varma B (1970) The effects of cholinomimetic drugs on responses to sympathetic nerve stimulation and noradrenaline in the rabbit ear artery. Br J Pharmacol 38:758–770PubMedGoogle Scholar
  81. Rathbun FJ, Hamilton JT (1970) Effect of gallamine on cholinergic receptors. Can Anaesth Soc J 17:754–790CrossRefGoogle Scholar
  82. Riker WF, Wescoe WC (1951) The pharmacology of Flaxedil with observations on some of its analogs. Ann NY Acad Sci 54:373–391PubMedCrossRefGoogle Scholar
  83. Roizen MF, Freeley T (1978) Diagnosis and treatment. Drugs five years later. Pancuronium bromide. Ann Intern Med 88:64–68PubMedGoogle Scholar
  84. Salt PJ, Barnes PK, Conway CM (1980) Inhibition of neuronal uptake of noradrenaline in the isolated perfused rat heart by pancuronium and its homologues, Org 6368, Org 7268 and Org NC 45. Br J Anaesth 52:313–317PubMedCrossRefGoogle Scholar
  85. Savage DS (1980) Mechanisms of action of muscle relaxants and relationships between structure and activity. In: Conseiller C et al. (eds) Curares and curarisation. Elsevier/ North Holland, New York, pp 21–31Google Scholar
  86. Savage DS (1981) Prinzipien der chemischen Struktur des idealen Muskelrelaxans. In: Bu-zello E (ed) Muskelrelaxantien. Georg Thieme, Stuttgart, pp 190–195Google Scholar
  87. Savage DS, Cameron AF, Ferguson G, Hannaway C, Mackay IR (1971) Molecular structure of pancuronium bromide (303b1,1703b2diacetoxy-203b2dipiperidino-503b1-androstane di-methobromide), a neuromuscular blocking agent. Crystal and molecular structure of the water: methylene chloride solvate. J Chem Soc B 410–415Google Scholar
  88. Savage DS, Sleigh T, Carlyle I (1980) The emergence of Org NC 45, l-[(203b2,303b1,503b1,1603b2,1703b2)-3,17-bis(acetyloxy)-2-(1 -piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 52:3–9SGoogle Scholar
  89. Saxena PR, Bonta IL (1970) Mechanism of selective cardiac vagolytic action of pancuronium bromide. Specific blockade of certain cardiac muscarinic receptors. Eur J Pharmacol 11:332–341PubMedCrossRefGoogle Scholar
  90. Shepherd JT, Lorenz RR, Tyce GM, Vanhoutte PM (1978) Acetylcholine-inhibition of transmitter release from adrenergic nerve terminals mediated by muscarinic receptors. Fed Proc 37:191–194PubMedGoogle Scholar
  91. Tomlinson DR (1979) On the mechanism of pancuronium-induced super sensitivity to noradrenaline in rat smooth muscle. Br J Pharmacol 65:473–478PubMedGoogle Scholar
  92. Torda TA, Kiloh N (1982 a) Org NC 45 reduces quantal release of acetylcholine; a preliminary communication. Anaesth Intensive Care 10:127–129PubMedGoogle Scholar
  93. Torda TA, Kiloh N (1982b) Myoneural actions of Org NC45. Br J Anaesth 54:1217–1222PubMedCrossRefGoogle Scholar
  94. Ungerer MJ, Erasmus FR (1974) Clinical evaluation of a new non-depolarizing relaxant. S Afr Med J 48:2561–2564PubMedGoogle Scholar
  95. Upton RA, Nguyen TL, Miller RD, Castagnoli N (1982) Renal and bilary elimination of vecuronium (Org NC 45) and pancuronium in rats. Anesth Analg (Cleve) 61:313–316Google Scholar
  96. Vanhoutte PM (1977) Cholinergic inhibition of adrenergic transmission. Fed Proc 36:2444–2447PubMedGoogle Scholar
  97. Vanhoutte PM, Levy MN (1980) Prejunctional cholinergic modulation of adrenergic neurotransmission in the cardiovarscular system. Am J Physiol 238:H275PubMedGoogle Scholar
  98. Vercruysse P, Bossuyt P, Hanegreefs G, Verbeuren TJ, Vanhoutte PM (1979) Gallamine and pancuronium inhibit prejunctional and postjunctional muscarinic receptors in canine saphenous veins. J Pharmacol Exp Ther 209:225–230PubMedGoogle Scholar
  99. Walts LF (1975) Complications of muscle relaxants. In Katz RL (ed) Muscle relaxants. Elsevier/North Holland, New York, p 209 (Monographs in anaesthesiology, vol 3)Google Scholar
  100. Waud DR, Lee Son S, Waud BE (1978) Kinetic and empirical analysis of dose-response curves illustrated with a cardiac example. Life Sci 22:1275–1286PubMedCrossRefGoogle Scholar
  101. Whittaker M, Britten JJ (1980) Inhibition of the plasma Cholinesterase variants by pancuronium bromide and some of its analogues. Clin Chim Acta 108:89–94PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • W. C. Bowman
  • G. A. Sutherland

There are no affiliations available

Personalised recommendations